TY - JOUR
T1 - Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis
AU - RAVE-ITN Research Group
AU - Berti, Alvise
AU - Hillion, Sophie
AU - Hummel, Amber M.
AU - Son, Young Min
AU - Chriti, Nedra
AU - Peikert, Tobias
AU - Carmona, Eva M.
AU - Abdulahad, Wayel H.
AU - Heeringa, Peter
AU - Harris, Kristina M.
AU - Clair, E. William St
AU - Brunetta, Paul
AU - Fervenza, Fernando C.
AU - Langford, Carol A.
AU - Kallenberg, Cees G.M.
AU - Merkel, Peter A.
AU - Monach, Paul A.
AU - Seo, Philip
AU - Spiera, Robert F.
AU - Stone, John H.
AU - Grandi, Guido
AU - Sun, Jie
AU - Pers, Jacques Olivier
AU - Specks, Ulrich
AU - Cornec, Divi
N1 - Funding Information:
This study was supported by a research grant from the Vasculitis Foundation to DC and US (http://www. vasculitisfoundation.org/research/research-program/). The work was also supported in part by NIH grants R01 AI112844, R01 AI15 4598, and R01 AI147394 to JS; by NIH grant RC1AR058303 to PAM; and by funds from the Mayo Foundation for Education and Research and the Connor Group Foundation to US. DC received funds from the “Société Française de Rhumatologie” for this work. AB was supported by funds from the Vasculitis Foundation/Vasculitis Clinical Research Consortium fellowship and by the National Reference Center for Rare Autoimmune Diseases in Brest, France. PAM was supported by an Arthritis Investigator Award from the Arthritis Foundation. Genentech and Biogen Idec provided the study medications and partial funding. The ITN021AI RAVE Trial was conducted by the Immune Tolerance Network and sponsored by the National Institute of Allergy and Infectious Diseases of the NIH under contract N01 AI15416 and award number UM1AI109565. See Supplemental Acknowledgments for RAVE-ITN Research Group details.
Funding Information:
employee of Genentech during the conduct of the RAVE trial and previously received salary and Genentech stock. JS’s laboratory received funding from Evive Biotech. JS and RFS participated in the GiACTA trial (sponsored by Roche) blocking the IL-6 receptor with tocilizumab in giant cell arteritis and reported grant support and personal fees from Roche. US, PAM, FCF, JHS, and RFS have received research grants from Roche/Genentech. PAM and RFS also report consulting fees from Roche/ Genentech. Genentech and Biogen Idec provided partial funding for the study and donated the study medication but had no determinative role in the study design, the analyses, or the preparation of the manuscript. ANCA ELISA kits were donated by EUROIMMUN.
Publisher Copyright:
© 2021, Berti et al.
PY - 2021/11/22
Y1 - 2021/11/22
N2 - BACKGROUND. Little is known about the autoreactive B cells in antineutrophil cytoplasmic antibody- associated (ANCA-associated) vasculitis (AAV). We aimed to investigate tolerance checkpoints of circulating antigen-specific proteinase 3-reactive (PR3+) B cells. METHODS. Multicolor flow cytometry in combination with bioinformatics and functional in vitro studies were performed on baseline samples of PBMCs from 154 well-characterized participants of the RAVE trial (NCT00104299) with severely active PR3-AAV and myeloperoxidase-AAV (MPO-AAV) and 27 healthy controls (HCs). Clinical data and outcomes from the trial were correlated with PR3+ B cells (total and subsets). RESULTS. The frequency of PR3+ B cells among circulating B cells was higher in participants with PR3- AAV (4.77% median [IQR, 3.98%-6.01%]) than in participants with MPO-AAV (3.16% median [IQR, 2.51%-5.22%]) and participants with AAV compared with HCs (1.67% median [IQR, 1.27%-2.16%], P < 0.001 for all comparisons), implying a defective central tolerance checkpoint in patients with AAV. Only PBMCs from participants with PR3-AAV contained PR3+ B cells capable of secreting PR3-ANCA IgG in vitro, proving they were functionally distinct from those of participants with MPO-AAV and HCs. Unsupervised clustering identified subtle subsets of atypical autoreactive PR3+ memory B cells accumulating through the maturation process in patients with PR3-AAV. PR3+ B cells were enriched in the memory B cell compartment of participants with PR3-AAV and were associated with higher serum CXCL13 levels, suggesting an increased germinal center activity. PR3+ B cells correlated with systemic inflammation (C-reactive protein and erythrocyte sedimentation rate, P < 0.05) and complete remission (P < 0.001). CONCLUSION. This study suggests the presence of defective central antigen-independent and peripheral antigen-dependent checkpoints in patients with PR3-AAV, elucidating the selection process of autoreactive B cells.
AB - BACKGROUND. Little is known about the autoreactive B cells in antineutrophil cytoplasmic antibody- associated (ANCA-associated) vasculitis (AAV). We aimed to investigate tolerance checkpoints of circulating antigen-specific proteinase 3-reactive (PR3+) B cells. METHODS. Multicolor flow cytometry in combination with bioinformatics and functional in vitro studies were performed on baseline samples of PBMCs from 154 well-characterized participants of the RAVE trial (NCT00104299) with severely active PR3-AAV and myeloperoxidase-AAV (MPO-AAV) and 27 healthy controls (HCs). Clinical data and outcomes from the trial were correlated with PR3+ B cells (total and subsets). RESULTS. The frequency of PR3+ B cells among circulating B cells was higher in participants with PR3- AAV (4.77% median [IQR, 3.98%-6.01%]) than in participants with MPO-AAV (3.16% median [IQR, 2.51%-5.22%]) and participants with AAV compared with HCs (1.67% median [IQR, 1.27%-2.16%], P < 0.001 for all comparisons), implying a defective central tolerance checkpoint in patients with AAV. Only PBMCs from participants with PR3-AAV contained PR3+ B cells capable of secreting PR3-ANCA IgG in vitro, proving they were functionally distinct from those of participants with MPO-AAV and HCs. Unsupervised clustering identified subtle subsets of atypical autoreactive PR3+ memory B cells accumulating through the maturation process in patients with PR3-AAV. PR3+ B cells were enriched in the memory B cell compartment of participants with PR3-AAV and were associated with higher serum CXCL13 levels, suggesting an increased germinal center activity. PR3+ B cells correlated with systemic inflammation (C-reactive protein and erythrocyte sedimentation rate, P < 0.05) and complete remission (P < 0.001). CONCLUSION. This study suggests the presence of defective central antigen-independent and peripheral antigen-dependent checkpoints in patients with PR3-AAV, elucidating the selection process of autoreactive B cells.
UR - http://www.scopus.com/inward/record.url?scp=85120363030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120363030&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.150999
DO - 10.1172/jci.insight.150999
M3 - Article
C2 - 34618687
AN - SCOPUS:85120363030
SN - 2379-3708
VL - 6
JO - JCI insight
JF - JCI insight
IS - 22
M1 - e150999
ER -